Efficacy of AI and palbociclib in ER+ HER2- advanced breast cancer patients relapsing during adjuvant tamoxifen: An exploratory analysis of the PADA-1 trial.

François-Clément Bidard,Florence Dalenc,Thibault De La Motte Rouge,Barbara Pistilli,Caroline Cheneau,Catherine Delbaldo,Olfa Derbel,Claire Garnier-Tixidre,Nathalie Marques,Sandrine Marques,L Moreau,Frédérique Berger,Jérome Lemonnier,Anne Claire Hardy-Bessard,Suzette Delaloge,Thomas Bachelot

Efficacy of AI and palbociclib in ER+ HER2- advanced breast cancer patients relapsing during adjuvant tamoxifen: An exploratory analysis of the PADA-1 trial.

2021

François-Clément Bidard
Florence Dalenc
Thibault De La Motte Rouge
Barbara Pistilli
Caroline Cheneau
Catherine Delbaldo
Olfa Derbel
Claire Garnier-Tixidre
Nathalie Marques
Sandrine Marques
L Moreau
Frédérique Berger
Jérome Lemonnier
Anne Claire Hardy-Bessard
Suzette Delaloge
Thomas Bachelot

1070Background: In PADA-1 (NCT03079011), a phase III trial testing the clinical utility of ESR1mut detection, ER+ HER2- advanced breast patients (ABC pts) received Aromatase Inhibitor (AI) and Palb...

Keywords:

Aromatase inhibitor
advanced breast
Oncology
Medicine
adjuvant tamoxifen
Cancer
Internal medicine
Palbociclib
exploratory analysis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations